Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709826 · ClinicalTrials.gov registry record · Phase 2
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
A Phase 2 study, sponsored by Tragara Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT00709826: Completed Phase 2 study, sponsored by Tragara Pharmaceuticals.
NCT00709826 is a Phase 2 study that has completed, run by Tragara Pharmaceuticals. The registered enrollment target is 109 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00709826, a Phase 2 study, has completed, sponsored by Tragara Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.
Primary Outcome
Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline.
Interventions
- DRUG placebo
- DRUG gemcitabine
- DRUG Erlotinib
- DRUG apricoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT00709826 record still lists
NCT00709826 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00709826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00709826 about?
NCT00709826 is a clinical study titled "APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer". This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.
What is the current status of trial NCT00709826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2008-08. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00709826?
The interventions under investigation include: placebo (DRUG), gemcitabine (DRUG), Erlotinib (DRUG), apricoxib (DRUG).
Who is sponsoring clinical trial NCT00709826?
This trial is sponsored by Tragara Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00709826's enrollment target sits among peer trials
109 640th of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia